

Three *Streptococcus pneumoniae* Sialidases: Three Different Products

Guogang Xu,^{†,‡} Milton J. Kiefel,[‡] Jennifer C. Wilson,[‡] Peter W. Andrew,[¶] Marco R. Oggioni,[§] and Garry L. Taylor^{*,†}

[†]Biomedical Sciences Research Complex, University of St. Andrews, KY16 9ST, U.K.

[‡]Institute for Glycomics, Griffith University Gold Coast Campus, Queensland 4222, Australia

[¶]Department of Infection, Immunity and Inflammation, University of Leicester, LE1 9HN, U.K.

[§]Dipartimento di Biologia Molecolare, Università di Siena, 53100, Italy


 Supporting Information

ABSTRACT: *Streptococcus pneumoniae* is a major human pathogen responsible for respiratory tract infections, septicemia, and meningitis and continues to produce numerous cases of disease with relatively high mortalities. *S. pneumoniae* encodes up to three sialidases, NanA, NanB, and NanC, that have been implicated in pathogenesis and are potential drug targets. NanA has been shown to be a promiscuous sialidase, hydrolyzing the removal of Neu5Ac from a variety of glycoconjugates with retention of configuration at the anomeric center, as we confirm by NMR. NanB is an intramolecular *trans*-sialidase producing 2,7-anhydro-Neu5Ac selectively from α 2,3-sialosides. Here, we show that the first product of NanC is 2-deoxy-2,3-didehydro-*N*-acetylneuraminic acid (Neu5Ac2en) that can be slowly hydrated by the enzyme to Neu5Ac. We propose that the three pneumococcal sialidases share a common catalytic mechanism up to the final product formation step, and speculate on the roles of the enzymes in the lifecycle of the bacterium.

Sialic acids are a group of nine-carbon carboxylated sugars widespread on the cell surfaces of animal tissues.¹ The removal of sialic acids from various glycoconjugates by sialidases (neuraminidases) is a key biochemical event associated with infection, apoptosis and signaling.² As shown in Scheme 1, sialidases typically hydrolyze sialoglycosides to release *N*-acetylneuraminic acid (Neu5Ac, **1**). Trypanosomal *trans*-sialidases can also hydrolyze sialosides, but their major function is to transfer Neu5Ac from α 2,3-sialosides to another sugar,³ while the leech intramolecular (IT) *trans*-sialidase produces 2,7-anhydro-Neu5Ac (**2**), instead of Neu5Ac (**1**).⁴

Streptococcus pneumoniae is a human pathogen responsible for respiratory tract infections, septicemia, and meningitis, and it expresses up to three sialidases, two of which (NanA, NanB) are validated pneumococcal virulence factors and potential drug targets.^{5–7} All three sialidases possess a carbohydrate-binding module (CBM) in addition to the catalytic domain. A study of clinical isolates of *S. pneumoniae* showed NanA, NanB, and NanC to be present in 100%, 96%, and 51% of strains, respectively, with NanC more prevalent in cerebrospinal fluid.⁷ NanA is anchored to the bacterium's outer membrane and its CBM has recently been shown to be a key determinant in enabling the bacterium to

Scheme 1. Reactions Catalyzed by Different Sialidases



cross the blood–brain barrier.⁸ Despite the fact that these three pneumococcal sialidases are known virulence factors, the precise function and role of these enzymes is less well understood. Therefore, the aim of this study was to characterize the sialidase activities of the three sialidases by NMR and kinetics, to see if any variation may help explain different roles in pneumococcal infection.

NanA had previously been shown to cleave α 2,3-, α 2,6-, and α 2,8-linked sialic acids using the thiobarbituric (TBA) assay.⁹ The ¹H NMR experiments herein show that NanA acts as a typical exosialidase, hydrolyzing α 2,3- or α 2,6-sialyllactose (3SL or 6SL) to release α -Neu5Ac (**1**). In solution, **1** then gradually mutarotates to β -Neu5Ac (**3**), the more stable isoform (Figure 1a for 3SL, Figure S4.1 for 6SL). Our previous NMR studies showed NanB to be an intramolecular *trans*-sialidase producing 2,7-anhydro-Neu5Ac (**2**) from α 2,3-sialosides⁹ and this has been confirmed in a crystal structure.¹⁰

The initial product of the NanC catalyzed cleavage of 3SL surprisingly failed to react in the TBA assay. ¹H NMR experiments showed that NanC initially makes only 2-deoxy-2,3-didehydro-*N*-acetylneuraminic acid (Neu5Ac2en, **4**) from 3SL (but not from 6SL) (Figure 1b), and this product is unable to react with TBA reagents. Although the sialidases from influenza B virus and *Vibrio cholerae* have been shown to release very small amounts of

Received: November 30, 2010

Published: January 18, 2011




Figure 1. ¹H NMR spectroscopy studies of (a) NanA, and (b) NanC with α,2,3-sialyllactose (3SL).

Table 1. Kinetic Analysis of the Pneumococcal Sialidases

	3SL		6SL	
	k_{cat} (min ⁻¹)	K_m (mM)	k_{cat} (min ⁻¹)	K_m (mM)
NanA	892.8 ± 15.9	0.64 ± 0.02	916.5 ± 27.3	2.17 ± 0.14
NanB	56.5 ± 6.4	2.39 ± 0.19	0.13 ± 0.01	0.15 ± 0.04
NanC	18.8 ± 3.1	1.08 ± 0.35	No activity	

Neu5Ac2en as a byproduct,^{11,12} NanC converts 3SL directly to Neu5Ac2en with a k_{cat} of ~19 min⁻¹ (Table 1).

Neu5Ac2en is a general sialidase inhibitor thought to mimic the transition-state sialyl cation in the sialidase mechanism. It inhibits NanA and NanB with a K_i of 2 μM and 0.3 mM, respectively.⁹ Upon 3SL depletion in the reaction, NanC starts to hydrate the accumulated Neu5Ac2en to Neu5Ac by attacking C2 at the axial position. In the ¹H NMR spectra (Figure 1b), this is reflected by the appearance after several hours of a unique doublet at δ2.05 ppm with a coupling constant of 5.05 Hz. Note that H3eq appears as a doublet because the NanC catalyzed hydration in D₂O introduces an axial deuterium at C3. This hydration reaction promoted by NanC was further confirmed by using pure Neu5Ac2en as the substrate (Figure S4.2). The NanC reaction with 3SL indicates this sialidase may adopt a ping-pong mechanism. Hydration of the alkene double bond by NanC is highly efficient and approximately 500-fold higher than that observed for *Clostridium perfringens* sialidase NanI.¹³ It is possible that the dual function of NanC,




Figure 2. Active sites of pneumococcal sialidases in the presence of Neu5Ac2en. (a) Topology of active sites colored by electrostatic potential. (b) Structural comparison of NanA (green; PDB code: 2vvz), NanB (blue; 2vw0), and NanC model (gold).

producing or eliminating Neu5Ac2en, may be dependent upon which substrate (a sialoside or Neu5Ac2en) is present in higher concentration.

Our ¹H NMR findings clearly show disparate catalytic properties of the three *S. pneumoniae* sialidases, which might play different but cooperative roles in pneumococcal virulence. NanA's role could be the first-line virulence factor for sialic acid removal; NanB produces 2,7-anhydro-Neu5Ac, which could be a nutritional source for the colonized bacteria, whereas NanC could be a regulator for NanA actions by producing or removing Neu5Ac2en from environments at different stages of pneumococcal infection.

We have previously reported the crystal structures of NanB and the catalytic domain of NanA.^{9,14} A model structure of NanC was made based on NanB, with which it shares 50% sequence identity. Structural comparisons show that NanA, NanB, and NanC present significantly different topologies around the active site (Figure 2a). In NanA, the catalytic cavity is flat and open, allowing easy access for various substrates or water molecules to aid hydrolysis. However, both NanB and NanC present a relatively narrow cleft for catalysis, due to the presence of a bulky tryptophan (Trp674 and Trp716 in NanB and NanC, respectively). This tryptophan is conserved in the leech sialidase⁴ and *Trypanosoma cruzi* transsialidase,³ where it provides a platform for an α,2,3-linked galactose, and sterically hinders α,2,6- and α,2,8-linked substrates. Moreover, Phe396 and Trp581 in NanC would further contribute to a hydrophobic environment for catalysis. Figure 2b depicts the active sites of the three pneumococcal sialidases, and shows that the residues forming the hydrophobic pocket accommodating the acetamido group also vary significantly between the sialidases.

In spite of the differences in hydrophobic residues around the active site, the three pneumococcal sialidases share conserved catalytic residues including a tri-arginine cluster that interacts with the carboxylate group of sialic acids, a nucleophilic tyrosine with its associated glutamic acid residue, an aspartic acid above the sugar




Figure 3. The proposed mechanisms of NanA, NanB, and NanC.

ring that acts as an acid/base, as well as a hydrophobic pocket accommodating the C-5 acetamido group (Figure 2b, Figure S3, Table S1). These are the features required for catalysis, which comprises a distortion of the sugar ring to a boat conformation (2B_5) upon binding and subsequent formation of a transition state with the formation of the 4H_5 half-chair oxocarbenium ion or covalently bonded intermediate in a 2C_5 chair form (Figure 3).

Given that the three pneumococcal sialidases have the requisite conserved catalytic residues to cleave sialosides, it is reasonable to conclude that it is the final product formation step which is different for each of the sialidases. As depicted in Figure 3, depending on attack at C-2 position of the oxocarbenium ion by different nucleophiles, such as a water molecule in hydrolytic sialidase, or the O-7 atom of the sialyl cation in IT *trans*-sialidase or another carbohydrate acceptor such as β Gal in *trans*-sialidase, the final products could be Neu5Ac, Neu2,7-anhydro5Ac, or Neu5Ac- β Gal. Here, *S. pneumoniae* NanA and NanB follow the mechanisms of a hydrolytic sialidase and an IT *trans*-sialidase, respectively.

In the first reaction to produce Neu5Ac2en, NanC might also adopt the generalized mechanism involving the formation of a transition-state sialyl cation or a covalently sialylated enzyme intermediate (Figure 3). However, in contrast to NanA and NanB, there must be no effective nucleophilic attack happening in the active site of NanC. This may in part be attributable to the hydrophobic environment created by residues stacking around the catalytic cleft, as well as the leaving lactose group covering on top. Furthermore, NanC can only form limited hydrogen bonds with Neu5Ac2en with a low K_i of ~ 3 mM. This also makes the

sialyl cation transition state less easily held by NanC, and it is therefore released as the transition-state analogue Neu5Ac2en (Figure 3). Mutations of Phe396 alone or with Trp581 allow NanC to produce some Neu5Ac, as well as Neu5Ac2en (Figures S4.3, S4.4).

The subsequent Neu5Ac2en hydration reaction probably only occurs at high concentrations of Neu5Ac2en, and presumably proceeds via a similar mechanism to that previously reported for catalysis by *C. perfringens* NanL.¹³ Briefly, the electrons in the nucleophilic π bond could attack the proton of the catalytic aspartic acid (Asp315), resulting in the formation of an oxocarbenium ion intermediate. Without any lactose covering on top, water molecules could be readily picked up and activated by Asp315. The water attacks the positive charge at C-2 position to produce a protonated intermediate, which transfers a proton back to Asp315, thus releasing Neu5Ac. An Asp315Ala mutant retains only 2% activity and lacks Neu5Ac2en hydrating capacity (Figures S4.5, S4.6), further confirming the role of Asp315 in catalysis. To discount the possibility of an elimination reaction, a thiosialoside substrate was examined with NanC by NMR, but this showed no activity (Figure S4.7).

The findings reported here, as summarized in Figure 3, add further evidence to the currently proposed sialidase mechanisms. By adopting distinct catalytic mechanisms, NanA, NanB, and NanC might work together to coordinate the sialidase action associated with pneumococcal virulence. Since the pneumococcal sialidases are potential drug targets, our findings show that, for each of the three distinct sialidases, different strategies may need to be considered for ongoing structure-based drug design.

■ ASSOCIATED CONTENT

S Supporting Information. Experimental details, 1H NMR spectra and sequence alignment data. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

glt2@st-andrews.ac.uk

Present Addresses

*Department of Respiratory Medicine, The Second Affiliated Hospital, Nanchang University, 1 Minde Road, Nanchang, China 330006.

■ ACKNOWLEDGMENT

G.X. was supported by BioCryst Pharmaceuticals, Inc. (Birmingham, AL). P.W.A. and M.R.O. were funded by the EU (Pneumopep). Authors thank Dr. Uli Schwarz-Linek, Dr. Robert Hagan, and Prof. Jim Naismith for kind help and useful discussions.

■ REFERENCES

- (1) Kiefel, M. J.; von Itzstein, M. *Chem. Rev.* **2002**, *102*, 471–90.
- (2) Taylor, G. *Curr. Opin. Struct. Biol.* **1996**, *6*, 830–7.
- (3) Amaya, M. F.; Watts, A. G.; Damager, I.; Wehenkel, A.; Nguyen, T.; Buschiazio, A.; Paris, G.; Frasch, A. C.; Withers, S. G.; Alzari, P. M. *Structure* **2004**, *12*, 775–84.
- (4) Luo, Y.; Li, S. C.; Li, Y. T.; Luo, M. *J. Mol. Biol.* **1999**, *285*, 323–32.
- (5) Manco, S.; Hernon, F.; Yesilkaya, H.; Paton, J. C.; Andrew, P. W.; Radioglu, A. *Infect. Immun.* **2006**, *74*, 4014–20.

- (6) Parker, D.; Soong, G.; Planet, P.; Brower, J.; Ratner, A. J.; Prince, A. *Infect. Immun.* **2009**, *77*, 3722–30.
- (7) Pettigrew, M. M.; Fennie, K. P.; York, M. P.; Daniels, J.; Ghaffar, F. *Infect. Immun.* **2006**, *74*, 3360–5.
- (8) Uchiyama, S.; Carlin, A. F.; Khosravi, A.; Weiman, S.; Banerjee, A.; Quach, D.; Hightower, G.; Mitchell, T. J.; Doran, K. S.; Nizet, V. *J. Exp. Med.* **2009**, *206*, 1845–52.
- (9) Xu, G.; Potter, J. A.; Russell, R. J.; Oggioni, M. R.; Andrew, P. W.; Taylor, G. L. *J. Mol. Biol.* **2008**, *384*, 436–49.
- (10) Gut, H.; King, S. J.; Walsh, M. A. *FEBS Lett.* **2008**, *582*, 3348–52.
- (11) Burmeister, W. P.; Henrissat, B.; Bosso, C.; Cusack, S.; Ruigrok, R. W. *Structure* **1993**, *1*, 19–26.
- (12) Moustafa, I.; Connaris, H.; Taylor, M.; Zaitsev, V.; Wilson, J. C.; Kiefel, M. J.; von Itzstein, M.; Taylor, G. *J. Biol. Chem.* **2004**, *279*, 40819–26.
- (13) Newstead, S. L.; Potter, J. A.; Wilson, J. C.; Xu, G.; Chien, C. H.; Watts, A. G.; Withers, S. G.; Taylor, G. L. *J. Biol. Chem.* **2008**, *283*, 9080–8.
- (14) Xu, G.; Li, X.; Andrew, P. W.; Taylor, G. L. *Acta Crystallogr., Sect. F: Struct. Biol. Cryst. Commun.* **2008**, *64*, 772–5.